ENMD-2076 was developed to test the hypothesis that anti-mitotic and broad anti-angiogenic activity could be combined in a single agent via inhibition of multiple targets including Aurora kinases, as well as vascular epithelial growth factor receptor 2 and fibroblast growth factor receptors 1 and 2. This first-in-human, phase I trial established that the dose of 160 mg/m 2 administered orally daily continuously was tolerable. ENMD-2076 demonstrated both biologic and antitumor activity in several cancer types, including those resistant to prior anti-angiogenic therapies. Consistent with inhibition of the target kinases, the primary dose-limiting toxicity was hypertension, usually manageable with single-agent anti-hypertensive therapy; non-dose-limiting neutropenia was also observed. Clinical efficacy was provocative in advanced platinum-resistant and -refractory ovarian cancer, with both radiographic and CA125 responses, justifying further exploration in this disease. The results also support continued development of agents that affect dual inhibition of tumor proliferation and angiogenesis. 
INTRODUCTION
The Aurora kinases are a family of serine/threonine kinases integral to mitotic cell division. Aurora A plays a key regulatory role in centrosome function during mitosis including formation of the bipolar mitotic spindle (1, 2) . Aurora B is a chromosomal passenger protein that plays a role in the attachment of chromosomes to the mitotic spindle and cytokinesis (3, 4) . The Auroras are overexpressed in many solid tumors and have been implicated in tumorigenesis (5, 6) .
Multiple Aurora kinase inhibitors are currently in preclinical or clinical development (7) .
Angiogenic kinases include vascular endothelial growth factor receptors (VEGFRs), plateletderived growth factor receptors (PDGFRs), and basic fibroblast growth factor receptors (bFGFRs). These receptors transduce signals from pro-angiogenic factors, promoting angiogenesis (8, 9) , the process by which tumors recruit their vascular supply (10).
Antiangiogenic agents can potentiate the effects of cytotoxic anti-cancer agents when used in combination. For example, the addition to chemotherapy of bevacizumab, a humanized monoclonal antibody directed at the pro-angiogenic factor VEGF, results in improved rate of response, progression free survival, and clinically meaningful increases in overall survival in advanced solid tumors such as colorectal cancer and non-small-cell lung cancer (11, 12).
ENMD-2076 was identified during the course of a focused synthetic medicinal chemistry effort directed toward discovery of novel inhibitors of Aurora kinases. However, in vitro assays defined the compound as an inhibitor of both Aurora and angiogenic kinases, targets of which include Aurora A (50% inhibitory concentration on recombinant kinase [IC 50 staining (13) .
In 28-day continuous oral dosing toxicology studies in rats and dogs, dose proportional increases in C max and AUC were seen. Gastrointestinal toxicities were observed in both species. In rats, liver function test abnormalities, bone marrow suppression and adrenal cortical changes occurred. Also observed were dental discoloration and breakage, as well as abnormalities of the femoral growth plate attributable to disruption of the vascular invasion that occurs at the cartilage/bone interface during the process of endochondral ossification; the latter is a possible signature toxicity of pharmacologically-induced inhibition of angiogenesis (17) . Many of these changes were reversible after a 28-day recovery period. Additionally, no cardiovascular or respiratory system safety signals emerged in telemeterized dogs. Taken together, preclinical toxicology, pharmacology and anti-tumor efficacy supported clinical assessment of ENMD-2076 in a first-in-human trial.
The principal objective of this study was to determine the maximum tolerated dose (MTD) of ENMD-2076 administered orally with continuous daily dosing in patients with advanced solid tumors. Secondary objectives included assessment of the toxicity profile, pharmacokinetics, pharmacodynamic effects on plasma soluble VEGFR2 and preliminary antitumor activity. The protocol was approved by the institutional review boards of participating institutions, and written informed consent was obtained for all patients prior to performing study-related procedures in accordance with federal and institutional guidelines.
Drug administration and dose-escalation procedures
ENMD-2076 was supplied by EntreMed, Inc (Rockville, MD) and total daily dose was calculated based on body surface area. ENMD-2076 was supplied as capsules of various strengths and was orally administered to fasting patients on a once daily continuous dosing
schedule. An exception to this was a 7-day observation period at the completion of cycle 1, prior For the dose-escalation portion of the study, patients were enrolled sequentially into escalating dosing cohorts using a standard 3(to 4) +3 design. Initially, 5 dose levels were pre-determined, but subsequently modified based on toxicity. Intra-patient dose escalation was not permitted. 
Pharmacokinetic sampling and assay
In the dose escalation portion, blood samples were collected in sodium heparin tubes immediately prior to the first dose on cycle 1, day 1 and then at 0. Skin biopsies were performed in a subset of patients enrolled in the MTD expansion arms.
Formalin-fixed, paraffin-embedded samples were analyzed by immunohistochemistry using an anti-phospho-histone H3 (pHH3) antibody (Cell Signaling Technology, Danvers, MA) as a marker of Aurora inhibition (19) .
Statistical Methods
Descriptive statistics were used for baseline characteristics, safety assessments, pharmacokinetic variables (including C max , T max , AUC 0-inf and t 1/2 ) and exploratory assessments, including time to progressive disease, tumor response and pHH3 immunohistochemistry in keratinocytes.
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RESULTS

Patient Demographics and Treatment
Sixty-seven patients, 29 in the dose-escalation portion and 38 in the MTD expansion, were enrolled from April 2008 to October 2009 (Table 1) . A total of 257 cycles were administered.
The median number of cycles per patient was 3 (range, 1-24). Reasons for study discontinuation were progressive disease in 41 patients (61%), an adverse event in 6 (9%) and other reasons in 11 (17%). At the time of data analysis, nine patients (13%) continue on treatment. 
Dose escalation and determination of maximum tolerated dose
Safety
The most frequently observed drug-related adverse events seen in all courses were hypertension, nausea and/or vomiting, fatigue, and diarrhea (Table 3; Supplementary Tables S1 and S2 Hypertension was seen in 55% of total patients, occurred at all dose levels and reached grade 3/4 severity in 21% (Table 3) . In most cases, hypertension was easily controlled with addition of one anti-hypertensive agent (71%), most commonly a dihydropyridine calcium channel blocker or an angiotensin-converting enzyme inhibitor. Hypertension resulted in dose delay or reduction in 16% of patients, but only resulted in study discontinuation for one patient. The median time to onset of hypertension following initial dosing was 14 days (range 2-60 days). A prior history of hypertension was noted in 46% of these patients. There was no correlation between the development of hypertension and clinical benefit (data not shown).
Neutropenia was first seen at 200 mg/m 2 during dose escalation in four of seven patients (57%); three of seven (43%) had grade 3 neutropenia requiring dose delay and reduction ( Oral mucosal-related complaints were common with ENMD-2076 treatment. In patients treated at all dose levels, 11/67 (16%) experienced glossodynia, 10/67 (15%) experienced mucositis, and 7/67 experienced (10%) dysgeusia. These AEs were more common at higher dosing levels, and Table 2 and individual events are listed in Supplementary Table S3 . In the MTD expansion, 14/38 (37%) required dose reduction.
The reasons for dose reduction in this group included: fatigue (n=5), hypertension (n=2), diarrhea (n=2), neutropenia (n=2), dyspnea (n=2), abdominal pain (n=1), hyponatremia (n=1), polycythemia (n=1) and mucositis (n=1). Dose reduction was based on multiple adverse events in three patients; only one patient was dose-reduced during the first cycle.
In the MTD expansion, 12/38 (32%) patients experienced 16 adverse events meeting DLT criteria. The majority of these (n=7) were due to hypertension of grade 3 (n=6) or grade 4 (n=1)
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Pharmacokinetic studies
Pharmacokinetic parameters were determined for ENMD-2076 and ENMD-2060, an active metabolite (Table 4) , and plasma concentrations plotted by dosing cohort (Fig. 1A, B and C) .
The absorption kinetics of ENMD-2076 were rapid after single and multiple doses with time to maximum observed plasma concentration (T max ) ranging from 3.0 to 7.8 hours for day 1 and 2.7 to 4.7 for day 28 over all dose levels. The mean terminal phase elimination half-life (t 1/2 ) after a single dose is estimated to range from 27.3 to 38.3 hours and from 44.9 to 53.1 hours after multiple doses. Using non-compartmental modeling, the maximum plasma concentration (C max ) and area under the plasma concentration-time curve (AUC 0-inf ) were dose proportional after single and multiple doses ( Fig. 1D and E) . With continuous daily dosing during cycle 1, accumulation of ENMD-2076 was observed with an average factor of 3.4 (±1.1) across all doses (C max day 28/C max day 1). However, additional accumulation was not seen based on analysis of subsequent trough levels in a subset of patients who remained on study for greater than 2 cycles (Supplementary Fig. S1 ).
The active metabolite, ENMD-2060, reached a maximum plasma concentration (C max ) between 6.0 to 19.4 hours on day 1 and 2.7 to 11.4 hours on day 28. ENMD-2060 had a longer t 1/2 than ENMD-2076, which ranged from 89.9 to 139 hours, and by linear regression, there was a significant inverse correlation between t 1/2 and dose cohort (P = 0.0171). There was no statistically significant dose proportionality in either AUC 0-inf or C max for ENMD-2060 (Fig. 1F) .
on Fig. S2A , B and C). Patient weight also correlated with ENMD-2060 fixed dose corrected C max (P = 0.0093) for day 28 ( Supplementary Fig. S2D ). No other correlations between patient characteristics and pharmacokinetic parameters were observed.
Pharmacodynamic Analysis: plasma sVEGFR2
The effect of ENMD-2076 on plasma sVEGFR2 was determined after 28 days of continuous dosing. The mean plasma sVEGFR2 decreased from 8419 pg/ml (95% CI 7716, 9122) at cycle 1, day 1 to 5600 pg/ml (95% CI 5086, 6113) at cycle 1, day 28 (p<0.001) ( Fig. 2A) . A decrease in sVEGFR2 at day 28 compared to baseline was seen in all dosing cohorts (Fig. 2B) , and persisted through multiple treatment cycles (data not shown). There was no association between percent decrease in sVEGFR2 and maximum decrease in tumor measurements by modified RECIST by
Pearson's Correlation (r 2 = 0.027, P = 0.28).
Histone H3 Phosphorylation in Keratinocytes
Pre-treatment and on-treatment (cycle 1, day 28) skin biopsies were obtained from 9 patients treated at the MTD and analyzed by immunohistochemistry to determine if there was a consistent
Research. Table S4 and Supplementary Fig. S3 ).
Antitumor Activity
Fifty-eight out of 67 patients were evaluable for tumor response. Of these, two patients (3%) had partial responses (PR) (1 confirmed), 49 had stable disease (SD) (85%) and 7 had progressive disease (PD) (12%) as their best response (Fig. 3 ). Both patients with PR have ovarian cancer. In this heavily pretreated population, including 67% having received prior anti-angiogenic agents, prolonged clinical benefit was seen in patients with a variety of solid tumors, notably in 
